The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory systolic blood pressure of 21mmHg from baseline at six months after implantation in patients with resistant hypertension. The study was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain) and published in The Lancet.
Deep venous stenting has become increasingly used to treat patients with pathological obstruction of venous return in the femoro-iliocaval venous segment following the development of new dedicated venous stents. Patients treated range from those with an isolated non-thrombotic iliac vein lesion, to those with extensive post-thrombotic disease requiring extensive reconstruction. In this commentary article, Adam Gwozdz writes that the challenges when treating these different groups of patient can vary and the postoperative anticoagulation management often requires personalisation.
More than 25% of the adult population is affected by varicose veins, with more than a 15% prevalence of chronic venous insufficiency (C3–C6), which induces a considerable burden on the health of these patients. The Bonn Vein Study found that 21% of the adult population had venous reflux >0.5s. For several reasons, such as low awareness, difficulty in diagnosing, and lack of recognition of the disabling nature of this disease, the severity of the health problems caused by chronic venous disease is poorly acknowledged, and it has received, until now, little recognition from public health care systems, which focus their attention on lifethreatening conditions, Armando Mansilha writes.
Leg ulceration is the poor relation of vascular disease, yet, as Sophie Renton writes, it is a very common problem. It is estimated that 1/1,000 people in the UK will have a leg ulcer at some stage in their lives. Leg ulcers become more common with ageing and by age 80 and above, approximately 20/1,000 people will have a leg ulcer. Renton presented on the new guidelines at the Venous Forum held at the Royal College of Medicine in London from 11–12 July.
Coming from a non-medical background, Keith Poskitt is unable to pinpoint exactly how his interest in the field developed. At school, science and sports—rugby and cricket in particular—vied for his attention. Following a serious ankle injury at the age of 19, any dreams of a sporting career were dashed. Luckily for the venous field, this set Poskitt firmly on the medicinal career path. He spoke to Venous News about the current state of venous medicine, what future developments he is keeping tabs on, and the important personal and professional lessons he has learned over the course of his varied and influential career.
Marianne De Maeseneer already wanted to become a doctor by the age of 12, with her imagination captured by the idea of working in developing countries. A “series of coincidences” led her towards vascular and venous medicine, in which she decided to make a career. De Maeseneer spoke to Venous News about her journey to become a venous specialist, and shares some of the most notable experiences and lessons taken from her varied career.
Nick Morrison chose venous medicine as he wanted a challenging career. Although he initially worried that he would become bored working in the venous field, his long and distinguished career since then is proof of the complexity and depth of the venous and endovenous space. Morrison spoke to Venous News about his current research interests and professional goals, his volunteer medical organisation, and the advice he would give to young physicians embarking on a career in venous and endovenous medicine.
Continuing work to develop an improved percutaneous valvuloplasty procedure “is promising”, said Johann Chris Ragg (Angioclinic Vein Centers, Berlin, Munich, Germany, and Zurich, Switzerland), as he updated delegates on the technique at the annual American College of Phlebology meeting (ACP; 2–5 November, Austin, USA). He also argued that now is the time to “prepare the stage” for this treatment, primarily by recognising early phase reflux as its own specific disease.
ManaMed has introduced PlasmaFlow, the first US Food and Drug Administrator-approved portable and tubeless deep vein thrombosis (DVT) prevention device throughout the USA.
The VIDIO study, led by Paul Gagne, Southern CT Vascular Center, Darien, USA, showed that intravenous ultrasound (IVUS) is more sensitive for assessing treatable iliofemoral vein stenosis compared with multiplanar venography and frequently leads to revised treatment plans and the potential for improved clinical outcome.
Twelve-month results from the SENTRY trial evaluating the Sentry bioconvertible inferior vena cava (IVC) filter (Novate) have shown a 0% rate of symptomatic pulmonary embolism, no instances of device failure and a 96% rate of bioconversion. Presenting that data at the Vascular Interventional Advances 2017 conference (VIVA; 11–14 September, Las Vegas, USA), principal investigator Michael Dake (Stanford, USA) said that the data represent “an important paradigm shift in the prevention of pulmonary embolism”.
Spectranetics has recalled the Bridge occlusion catheter “due to the possibility of a blocked guidewire lumen in some device units”. Using affected catheters could lead to the incorrect positioning of the device and subsequent uncontrolled haemorrhage.
A study has shown modified human factor X to be a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants. This new therapeutic factor X was inspired by a snake venom protein.
Data from the LAMA (Laser ablation versus mechanochemical ablation) trial indicate that mechanochemical ablation (MOCA) is significantly less painful than endovenous laser ablation (EVLA) during treatment of superficial venous incompetence, though there is no difference in pain between the two treatments when the pain of phlebectomy is taken into account. Both techniques significantly improved clinical severity and quality of life in this trial.
The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European Society of Cardiology (ESC) Working Group on Aorta and Peripheral Vascular Diseases and Working Group on Pulmonary Circulation and Right Ventricular Function.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos